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aSaudi ArabiaBackground: Drug-eluting stents (DES) are used in the majority of patients who undergo percutaneous coronary
intervention (PCI), and have reduced the rate of in-stent restenosis and repeated revascularization in comparison to
bare metal stents. However, stent thrombosis (ST) is an uncommon but serious complication of coronary artery stents
that is mostly fatal or presents as a large non-fatal myocardial infarction (MI), usually with ST elevation.
Objective: To study the incidence of stent thrombosis in Middle Eastern Saudi patients who underwent PCI using
both drug-eluting stents (DES) and bare metal stents (BMS). ST can occur acutely (within 24 h), sub acutely (within
30 days), or as late as one year (late) or even more than one year (very late).
Methods: In an observational, single center study in catheterization (cath) lab a total of 1386 patients underwent
PCI between January 2008 and September 2010. The study included all patients in that period who had acute coro-
nary syndrome and stable coronary artery disease (CAD).
Results: A total of 1386 patients had PCI and stent deployments; 19 (1.3%) patients had stent thrombosis, four
patients (21%) received BMS and 15 patients (79%) received DES. Four patients had acute ST; five had subacute
ST; eight patients had late ST; while two patients had very late ST. Nine patients (47%) had DM and eight patients
(42%) had hypertension.
Conclusion: The incidence of ST in Saudi patients who received DES at our center is similar to internationally
reported numbers. Almost half of ST patients are diabetics and there is increasing concern that the risk for late stent
thrombosis is slightly higher with DES than BMS.
 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.
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Abbreviations and Acronyms
DES = drug eluted stent
PCI = percutaneous coronary intervention
ST = stent thrombosis
CAD = coronary artery disease
BMS = bare metal stent
MI = myocardial infarction
DAPT = dual anti platelet therapy
ARC = academic Research consortium
STEMI = ST elevation myocardial infarction
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Intervention in coronary artery disease using thenew stents is currently practiced because it
decreases the need for repeat target vessel revas-
cularization compared to balloon angioplasty.
Stent thrombosis is not very common but it is
a dangerous complication, with most patients
presenting with either fatal or non-fatal
myocardial infarction (MI). MI has a typical ST
segment elevation, and, according to previous
studies, <10% of cardiac deaths are due to ST
while others are due to the progression of ath-
erosclerosis [1].
Dual antiplatelet therapy (DAPT) using aspirin
and thienopyridine both in acute coronary syn-
drome patients and in elective stable coronary ar-
tery disease lead to significant reduction in
incidence of ST (<2%), and no major bleeding
[2,3].
Various studies show that a loading dose and
pretreatment with thienopyridines plus the use
of glycoprotein IIb/IIIa inhibitors during ACS
and stenting will reduce ST [4].
Stent thrombosis can occur acutely (within 24 h),
subacutely (within 30 days), or as late as one year
(late) or more (very late) after stent placement.
There is similar frequency of stent thrombosis
within the first year in both BMS and DES. Due
to delayed endothelialization and neointimal cov-
erage, a longer duration of dual antiplatelet ther-
apy is recommended with DES [5].
One of the major benefits of DES is the major
reduction in in-stent restenosis and repeat target
vessel revascularization, which could be due to
inhibition of neointimal hyperplasia in compari-
son with BMS. However, longer term follow-up
in more complex patients and lesions have led to
the recognition of another nuisance: very late
stent thrombosis [6,7].
The issue of ST was raised during a meeting of the
European Society of Cardiology in Barcelona in
2006. Research for this important topic of ST was
subsequently initiated and has become a major
concern in interventional cardiology today [8].Methods
A retrospective study was carried out in our
cardiac center between January 2008 and Sep-
tember 2010. In this single center study, a total
of 1386 patients underwent percutaneous coro-
nary intervention (PCI) and stent deployment.
All patients in that period included in this study
either presented with acute coronary syndrome
or stable coronary artery disease (CAD). Onlypatients with definite stent thrombosis or filling
defect by coronary angiography were included
in this study.
This study was approved by the research
committee at King Abdullah International Medi-
cal Research Center. Patients who presented with
stent thrombosis agreed to sign an informed
consent for inclusion in the study.
This study was a personal effort, with no fund-
ing from an external source. All protocols were
in compliance with the Declaration of Helsinki.Angiographic analysis
Angiographic analysis included initial and final
lesion assessment of the stented segment. Hazi-
ness and thrombus formation inside the stent
were evaluated in all patients who underwent
repeated coronary angiography. Visual assess-
ments were performed off-line by two blinded
interventional cardiologists.Stent thrombosis
Definition and classification
A definition of stent thrombosis was proposed
by the Academic Research Consortium (ARC) to
standardize interpretation of frequency of stent
thrombosis across different trials and registries.
The ARC is composed of clinical investigators,
industry representatives and regulators including
the Food and Drug Administration, and the defi-
nition categorizes stent thrombosis according to
the level of documentation and timing [9].Definite
Angiographic confirmation of a thrombus that
originates in the stent or in the segment 5 mm
proximal or distal to the stent, with or without ves-
sel occlusion, which is associated with acute onset
of ischemic symptoms at rest or ECG signs of
acute ischemia or typical rise and fall in cardiac
biomarkers within 48 h of angiography or patho-
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Figure 3. Stent thrombosis was shown according to the time of
presentation.
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Figure 4. Stent thrombosis distribution in coronary arteries.
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Table 1. Baseline characteristics in
patients with stent thrombosis; data
presented as n (%).
Overall (n = 19)
Mean age 59 year
Male sex 19 (100)
HTN 8 (42)
DM 9 (47)
Smokers 7 (37)
Hyperlipidemia 19 (52)
DES 15 (79)
BMS 4 (21)
Abbreviations: HTN, hypertension; DM,
diabetes mellitus; DES, Drug-eluted
stent; BMS, bare metal stent.
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Figure 1. 19 patients out of 1386 had stent thrombosis.
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Figure 2. Stent thrombosis was seen in DES and BMS groups.
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from tissue obtained following thrombectomy.Statistical methods
Continuous variables were presented as
mean + SD or median and range, if appropriate.
Discrete variables were expressed as counts and
percentages. All statistical analyses were per-
formed with JMP version 8.0 (SAS Institute, Cary,
North Carolina).Results
Out of 1386 patients included in the study, 19
patients presented with stent thrombosis (Table
1).
Age 30–80 with mean 59 years, 100% male, nine
patients (47%) had DM and eight patients (42%)
had hypertension, 10 patients had hyperlipidemia
(52%), and seven patients were smokers (37%).
A total of 1386 patients had PCI and stents
deployment, 19 patients (1.3%) developed stent
thrombosis (Fig. 1), four patients (21%) received
BMS, and 15 patients (79%) received DES (Fig. 2).
Acute ST was found in four patients, subacute
ST in five patients, late ST in eight patients, and
very late ST was found in two patients (Fig. 3).
ST according to coronary anatomy, LAD ST in 12
patients, RCA ST in five patients, and circumflex
ST in two patients (Fig. 4).Discussion
This study carried out in a single cardiac center.
The rationale for this study was derived from the
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with ST than with BMS. As far as we know, this
is the first study from our area to announce the
rate of ST in Middle Eastern patients.
One of the major findings of this study is that
the rate of ST was almost similar to the previous
international rate of 1.3%, and most patients pre-
sented with late stent thrombosis.
It is well known that both anticoagulation and
antiplatelets have a significant role in preventing
both acute and sub-acute ST during coronary
stenting.
In the HORIZON-AMI trial, anticoagulation
with bivalirudin alone, as compared with heparin
plus glycoprotein IIb/IIIa inhibitors, resulted in a
reduction of a 30-day rate of net adverse clinical
events, owing to a lower rate of major bleeding.
The risk of acute ST increased in the bivalirudin
group, but no significant increase was present by
30 days. Treatment with bivalirudin alone, as com-
pared with heparin plus glycoprotein IIb/IIIa
inhibitors, resulted in significantly lower 30-day
rates of death from cardiac causes [10].
Prasugrel, a novel thienopyridine with a more
predictable inhibition of platelet aggregation, has
been shown to reduce early stent thrombosis by
71% compared with clopidogrel (0.42% versus
1.44%, hazard ratio = 0.29, 95% CI 0.15–0.56,
P = 0.0001) in patients with acute coronary syn-
dromes treated with either bare metal or drug-
eluting stents [11]. This agent appears particularly
beneficial in patients at increased risk of stent
thrombosis, such as diabetics and those with ST-
segment elevation myocardial infarction (STEMI),
without a disproportionately increased risk of
bleeding in these subgroups.
The absolute rates of early definite (0.9%), and
definite or probable stent thrombosis (1.4%) in the
present study are clearly higher compared with
the incidence of early stent thrombosis in stable pa-
tients undergoing PCI under elective conditions
(0.3–0.4%). Yet the results correspond well to the
1.4% rate of early definite or probable stent throm-
bosis recently reported for the clopidogrel arm of
patients included in another acute coronary syn-
drome trial, the Trial to Assess Improvement in
Therapeutic Outcomes by Optimizing Platelet
Inhibition with Prasugrel-Thrombolysis in Myo-
cardial Infarction (TRITON-TIMI) 38. The risk of
early stent thrombosis in patients with acute coro-
nary syndromes is increased due to accumulation
of several simultaneous prothrombotic conditions,
such as local thrombus burden at the site of plaque
rupture, impaired flow due to distal embolization
with obstruction of the microcirculation, incom-plete stent apposition related to dissolution of ini-
tially jailed material or stent mismatch (undersize
or underexpansion), vulnerable plaque with necro-
tic components, plaque prolapse through stent
struts into the lumen, impaired healing capacity, a
procoagulable state, incomplete inhibition of plate-
let activation, and impaired left ventricular func-
tion. In analogy to the bare metal stent era, early
stent thrombosis with drug-eluting stents repre-
sents a risk continuum largely determined by the
clinical setting, ranging from low risk in patients
with stable coronary artery disease, to intermediate
risk in patients with acute coronary syndromes, and
extending to high risk in patients with acute STEMI
[11].
As previously reported, the Acute Catheteriza-
tion and Urgent Intervention Triage Strategy
(ACUITY) trial randomly assigned 13,819 patients
with moderate- to high-risk acute coronary syn-
dromes to one of three antithrombotic regimens:
heparin plus a glycoprotein IIb/IIIa inhibitor, biv-
alirudin plus a glycoprotein IIb/IIIa inhibitor, or
bivalirudin alone. The present analysis is based
on the quantitative coronary angiography sub-
group of 3405 patients (25%) in the ACUITY-PCI
substudy. Definite or probable stent thrombosis
within 30 days was encountered in 48 of 3405 pa-
tients (1.4%) in the overall population, in 43 of
3043 patients (1.4%) treated with drug-eluting
stents, and in five of 362 patients (1.4%) treated
with bare metal stents [12].
In a 2012 prospective observational study of 6166
unselected patients who received either EES or
SES, the rates of stent thrombosis at two years
were similar (hazard ratio 1.16, 95% CI 0.47–2.84,
comparing EES to SES) [13]. Rates of stent throm-
bosis between EES and R-ZES have been evalu-
ated in the RESOLUTE All Comers and
TWENTE randomized trials, neither of which
was powered to detect differences in these rates
[14,15] (See ‘Comparison of drug-eluting intracor-
onary stents’, section on ‘Everolimus- versus zota-
rolimus-eluting stents’.) In these two trials, the
rates of definite or probable stent thrombosis were
low and not significantly different in the two
groups at one year or later.
In a study of 8791 patients who were randomly
assigned to either E-ZES (an older version of
ZES) or a SES, the rates of definite or probable
stent thrombosis were similar at three years (1.4
versus 1.8%) [16].Future prevention of stent thrombosis
Stents coated with new cytotoxic drugs and
polymers may have different properties in terms
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CENTER EXPERIENCEof affecting endothelialization, vascular inflamma-
tion and induction of tissue factor activity. Coating
with NO-donors may decrease platelet adhesion
and aggregation. Stents coated with CD34-anti-
bodies may capture circulating endothelial pro-
genitor cells and may be able to prevent
thrombosis by increasing and accelerating endo-
thelial coverage [17].
Furthermore, development of biodegradable
stents might also be a way to decrease the inci-
dence of late and very late stent thrombosis [18].
Development of new tests able to assess platelet
inhibition may identify patients with a reduced
benefit from aspirin or clopidogrel and may make
it possible to further individualize and optimize
anti-platelet therapy [19].
In long-term analyses, defined as greater than
one year, mortality and MI findings were similar
to those observed in the short term. Long term,
there was a significant 18–37% reduction in risk of
MI with all DES compared with bare-metal stents,
with the exception of PES. Overall, EES had the low-
est MI rate. Regarding the long-term safety of the
stents, ‘any’ stent-thrombosis rates were similar
for DES compared with bare metal stents, with
the exception of EES, which showed a significant
49% reduction in the risk of stent thrombosis. For
between-stent comparisons, SES had lower rates
of stent thrombosis than PES, and EES was superior
to SES, PES, and the older ZES [20].
Though evidence remains inconclusive, some
studies indicate that the incidence of late and very
late stent thrombosis is increased after DES
implantation.
Importantly, it is unknown whether very late
stent thrombosis is a time limited phenomenon
and, thus, that the problem might increase if
events continue to accrue over time.
As a consequence, large-scale clinical trials with
long-term follow-up as well as mechanistic studies
are highly warranted. Currently, it is not known
whether very late stent thrombosis is prevented with
an extended course of dual anti-platelet therapy.
Certainly, the issue of stent thrombosis empha-
sizes the importance of careful patient selection
and individualized therapy which, in future,
might partly be based on measurement of the
intensity of platelet inhibition.Conclusion
The incidence of ST in our Saudi patients who
received DES is similar to internationally reported
numbers. Almost half of ST patients are diabetics
and there is increasing concern that the risk forlate stent thrombosis is slightly higher with DES
than with BMS.Limitation of the study
This study was a single center study, and patient
numbers and samples are medium-sized com-
pared with international centers.Acknowledgment
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